澳大利亚昆士兰州儿童水痘疫苗规划的影响与效果
2005年11月澳大利亚为18月龄儿童公费引入单剂水痘疫苗;研究比较2000-2014年年龄标化水痘住院率,并用病例对照研究评估疫苗效果。2011-2014年水痘主诊断住院率由5.7降至1.6/10万,19月龄至6岁儿童防住院效果81.9%,19月龄至8岁儿童防急诊就诊效果57.9%。
要点
- 2011-2014年水痘主诊断住院率较2000-2003年下降超过70%,由5.7降至1.6/10万。
- 19月龄至6岁儿童单剂水痘疫苗防主诊断住院效果81.9%(95%CI 61.8-91.4%)。
- 19月龄至8岁儿童单剂水痘疫苗防急诊就诊效果57.9%(95%CI 48.5-65.5%)。
核心结论
- 澳大利亚单剂水痘疫苗接种规划已大幅降低水痘疾病负担。
- 单剂水痘疫苗对住院为中等至高度有效,但对急诊就诊似乎效果较低。
研究设计与样本
- 计算2000-2014年年龄标化水痘住院率,并比较公费资助前后时期。
- 采用病例对照研究,按出生日期和居住州从人群登记匹配对照,评估接种与住院及急诊就诊的关联。
- 疫苗效果按(1-比值比)×100%计算。
主要发现
- 与2000-2003年公费前时期相比,2011-2014年年龄标化水痘住院率下降超过70%。
- 水痘主诊断率由5.7/10万/年降至1.6/10万/年。
- 19月龄至6岁儿童防水痘主诊断住院的疫苗效果为81.9%(95%CI 61.8-91.4%)。
- 19月龄至8岁儿童防急诊就诊的疫苗效果为57.9%(95%CI 48.5-65.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In November 2005, Australia introduced a publicly funded single dose of varicella vaccine for children aged 18-months. We describe the impact of this program on varicella hospitalisations in Queensland and provide the first assessment of single-dose varicella vaccine effectiveness in Australia since the program commenced. METHODS: Age-standardised varicella hospitalisation rates were calculated for 2000-2014 and pre- and post-public funding period rates compared. Case-control studies were conducted to investigate the association between vaccine receipt and both varicella hospitalisations and uncomplicated varicella emergency department presentations. Cases were matched to controls from a population-based register by date of birth and state of residence. Vaccine effectiveness was calculated as (1-odds ratio)×100%. RESULTS: Compared to the pre-funded period (2000-2003), age-standardised varicella hospitalisation rates declined by more than 70% in 2011-2014 with varicella principal diagnosis rates declining from 5.7 to 1.6 per 100,000 population per year. Varicella vaccine effectiveness at preventing hospitalisation with a principal diagnosis of varicella among children aged 19-months to 6-years was 81.9% (95% confidence interval: 61.8-91.4%), while for emergency department presentations among children aged 19-months to 8-years it was 57.9% (95% confidence interval: 48.5-65.5%). CONCLUSIONS: In Australia, the single-dose varicella vaccination program has substantially reduced varicella morbidity. The single-dose varicella vaccine schedule is moderately-to-highly effective against hospitalisation, but appears less effective against emergency department presentations.
引用
- Sheridan SL, Quinn HE, Hull BP, et al. Impact and effectiveness of childhood varicella vaccine program in Queensland, Australia. Vaccine. 2017. PMID: 28528765. doi:10.1016/j.vaccine.2017.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。